After-Hours Stock Movers 10/18: (YHOO) Higher; (CREE) (VIVO) (MANH) Lower (more...)
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Cree (NASDAQ: CREE) 9.5% LOWER; reported Q1 EPS of $0.09, $0.02 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $321.3 million versus the consensus estimate of $322.77 million. GUIDANCE: Cree sees Q2 2017 EPS of $0.13-$0.19, versus the consensus of $0.15. Cree sees Q2 2017 revenue of $310-330 million, versus the consensus of $336.7 million.
Meridian Bioscience, Inc. (Nasdaq: VIVO) 9% LOWER; announced that based on preliminary results, it expects revenues for fiscal year 2016, ended on September 30, 2016, to be approximately $196 million, an increase of 1% compared to the prior year. Diluted earnings per share are expected to be $0.75 to $0.76, including costs related to acquisition activity and costs associated with the reorganization of Diagnostics sales and marketing leadership (in the aggregate, $1.7 million after tax or $0.04 diluted earnings per share). This compares to diluted earnings per share of $0.85 in fiscal 2015. *** The Street sees FY16 revenue of $198.5 million and EPS of $0.86.
Manhattan Associates, Inc. (NASDAQ: MANH) 8.5% LOWER; reported Q3 EPS of $0.45, $0.01 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $152.2 million versus the consensus estimate of $156.15 million. GUIDANCE: Manhattan Associates, Inc. sees FY2016 EPS of $1.82-$1.84, versus prior guidance of $1.78-$1.81 and the consensus of $1.79. Manhattan Associates, Inc. sees FY2016 revenue of $603-609 million, versus prior guidance of $615-620 million and the consensus of $615.98 million.
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) 6.7% LOWER; today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public offerings.
Puma Biotechnology, Inc. (NYSE: PBYI) 5.8% LOWER; announced that it is commencing an underwritten public offering of $150 million of shares of its common stock. Puma Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. All of the shares are being offered by Puma Biotechnology.
Intel (NASDAQ: INTC) 4.8% LOWER; reported Q3 EPS of $0.80, $0.08 better than the analyst estimate of $0.72. Revenue was $15.8 billion, versus $15.58 billion expected. Adjusted gross margin was 64.8 percent, versus 63.0 percent expected. Guidance: Sees Q4 revenue of $15.7 billion, +/- $800 million and gross margin percentage of 63 percent on a non-GAAP basis. The Street sees Q4 revenue of $15.86 billion.
Intuitive Surgical (NASDAQ: ISRG) 2.2% LOWER; reported Q3 EPS of $6.19, $1.06 better than the analyst estimate of $5.13. Revenue for the quarter came in at $683 million versus the consensus estimate of $650.49 million.
Yahoo! (NASDAQ: YHOO) 1.5% HIGHER; reported Q3 EPS of $0.20, $0.06 better than the analyst estimate of $0.14. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.31 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocean Power Technologies (OPTT) Reports Q2 Loss of $0.25/Share
- Pre-Open Stock Movers 12/09: (SWC) (SGYP) (FNSR) Higher; (XTLY) (RH) (DLTH) Lower (more...)
- Pre-Open Stock Movers 12/08: (VYGR) (TLRD) (LULU) Higher; (OHRP) (VRNT) (CMTL) Lower (more...)